Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update
Paula Morales, Laura Hernández‐Folgado, Pilar Goya, et al.
Expert Opinion on Therapeutic Patents (2016) Vol. 26, Iss. 7, pp. 843-856
Closed Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

New approaches and challenges to targeting the endocannabinoid system
Vincenzo Di Marzo
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 9, pp. 623-639
Closed Access | Times Cited: 412
Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products
Dongchen An, Steve Peigneur, Louise Antonia Hendrickx, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5064-5064
Open Access | Times Cited: 159
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 83
Cardiotoxic effects of common and emerging drugs: role of cannabinoid receptors
Yi-Ming Bo, Xin Zhao, Liliang Li
Clinical Science (2024) Vol. 138, Iss. 6, pp. 413-434
Closed Access | Times Cited: 24
An overview of the cannabinoid type 2 receptor system and its therapeutic potential
Bihua Bie, Jiang Wu, Joseph F. Foss, et al.
Current Opinion in Anaesthesiology (2018) Vol. 31, Iss. 4, pp. 407-414
Open Access | Times Cited: 158
Chronic pain patients' perspectives of medical cannabis
Brian J. Piper, Monica Beals, Alexander T. Abess, et al.
Pain (2017) Vol. 158, Iss. 7, pp. 1373-1379
Open Access | Times Cited: 101
CB2R Attenuates Intervertebral Disc Degeneration by Delaying Nucleus Pulposus Cell Senescence through AMPK/GSK3β Pathway
Jiacheng Du, Menglei Xu, Fanchen Kong, et al.
Aging and Disease (2022) Vol. 13, Iss. 2, pp. 552-552
Open Access | Times Cited: 46
Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties
Aya E. Ghonim, Alessia Ligresti, Alessandro Rabbito, et al.
European Journal of Medicinal Chemistry (2019) Vol. 180, pp. 154-170
Closed Access | Times Cited: 60
Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats
Jiang Wu, Mark Hocevar, Bihua Bie, et al.
Journal of Pain (2018) Vol. 20, Iss. 5, pp. 501-514
Open Access | Times Cited: 58
The Clinical Significance of Endocannabinoids in Endometriosis Pain Management
Jérôme Bouaziz, Alexandra Bar On, Daniel S. Seidman, et al.
Cannabis and Cannabinoid Research (2017) Vol. 2, Iss. 1, pp. 72-80
Open Access | Times Cited: 53
Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism
Paula Morales, Pilar Goya, Nadine Jagerovic
Biochemical Pharmacology (2018) Vol. 157, pp. 8-17
Closed Access | Times Cited: 47
Cannabinoid pharmacology: Research on medicinal cannabins and its therapeutic application
Vedangi Arvind Kulkarni, Himanshi Pramod Nimje, Pratiksha Purushottam Varhade, et al.
Journal of Pharmaceutical and Biological Sciences (2025) Vol. 12, Iss. 2, pp. 135-143
Closed Access
The relationship between cannabis and cardiovascular disease: clearing the haze
Mark Chandy, Nerea Jimenez-Tellez, Joseph C. Wu
Nature Reviews Cardiology (2025)
Closed Access
Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis
Pedro Melgar‐Lesmes, Meritxell Perramón, Wladimiro Jiménez
Cells (2019) Vol. 8, Iss. 11, pp. 1311-1311
Open Access | Times Cited: 35
Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist
Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N. Goyal, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 28
Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor
Sameek Singh, Caitlin R. M. Oyagawa, Christa MacDonald, et al.
ACS Medicinal Chemistry Letters (2019) Vol. 10, Iss. 2, pp. 209-214
Open Access | Times Cited: 35
Novel approaches and current challenges with targeting the endocannabinoid system
Paula Morales, Nadine Jagerovic
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 8, pp. 917-930
Open Access | Times Cited: 30
A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse
Xiaoyan Lin, Zhili Xu, Lawrence M. Carey, et al.
Pain (2021) Vol. 163, Iss. 5, pp. 834-851
Open Access | Times Cited: 25
Cannabinoid Receptor Type 2 Ligands: An Analysis of Granted Patents Since 2010
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, et al.
Pharmaceutical Patent Analyst (2021) Vol. 10, Iss. 3, pp. 111-163
Closed Access | Times Cited: 24
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential
Valeria Gasperi, Tatiana Guzzo, Alessandra Topai, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 12, pp. 1420-1457
Closed Access | Times Cited: 18
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)
Miroslav Kosar, Leonard Mach, Erick M. Carreira, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 665-700
Closed Access | Times Cited: 3
Cannabinoid receptor 2 (CB2) modulators: A patent review (2016–2024)
Rayees Ahmad Naikoo, Ritu Painuli, Zaheen Akhter, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107775-107775
Closed Access | Times Cited: 3
Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain
Sangdon Han, Lars Thoresen, Jae‐Kyu Jung, et al.
ACS Medicinal Chemistry Letters (2017) Vol. 8, Iss. 12, pp. 1309-1313
Open Access | Times Cited: 31
Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease
Claudia Mugnaini, Alessandro Rabbito, Antonella Brizzi, et al.
European Journal of Medicinal Chemistry (2018) Vol. 161, pp. 239-251
Open Access | Times Cited: 30
Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy
Anna-Maria Szczesniak, Richard F. Porter, James Thomas Toguri, et al.
Neuropharmacology (2016) Vol. 113, pp. 627-638
Closed Access | Times Cited: 29
Page 1 - Next Page

Scroll to top